Drugs / CBL0137
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03727789 | Jul 2019 → Jan 2024 | cutaneous melanoma, soft tissue sarcoma | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02931110 | Jan 2017 → Oct 2020 | hematopoietic and lymphoid cell neoplasm | Incuron | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01905228 | Jul 2013 → May 2019 | glioblastoma | Incuron | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04870944 | Jan 2022 → Dec 2026 expected | diffuse midline glioma, H3 K27-altered, lymphoma, metastatic malignant neoplasm in the brain | Children's Oncology Group | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBL0137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02931110 ↗ |
| Known as | NSC# 825802 | “A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma” NCT04870944 ↗ |
| Action | Inhibit | “Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell.” NCT04870944 ↗ |
| Modality | Other / unclassified | “FACT complex-targeting curaxin CBL0137” NCT03727789 ↗ |
| Route | Intravenous | “All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.” NCT01905228 ↗ |